Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 201703, 8 pages
http://dx.doi.org/10.1155/2015/201703
Review Article

Epigenetic Regulation of Inflammatory Cytokines and Associated Genes in Human Malignancies

1Department of Environmental Sciences, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan
2Institute of Basic Medical Sciences, Khyber Medical University, Peshawar 25124, Pakistan
3Institute of Biomedical and Genetic Engineering, Islamabad 54000, Pakistan

Received 12 January 2015; Accepted 18 February 2015

Academic Editor: Marc Pouliot

Copyright © 2015 Rehana Yasmin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Hirahara, A. Poholek, G. Vahedi et al., “Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease,” Journal of Allergy and Clinical Immunology, vol. 131, no. 5, pp. 1276–1287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. B. B. Aggarwal, “Nuclear factor-κB: the enemy within,” Cancer Cell, vol. 6, no. 3, pp. 203–208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Mason and P. Libby, “Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions,” European Heart Journal, 2014. View at Publisher · View at Google Scholar
  4. S. C. Pugliese, J. M. Poth, M. A. Fini, A. Olschewski, K. C. El Kasmi, and K. R. Stenmark, “The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 308, no. 3, pp. L229–L252, 2015. View at Publisher · View at Google Scholar
  5. G. Singhal, E. J. Jaehne, F. Corrigan, C. Toben, and B. T. Baune, “Inflammasomes in neuroinflammation and changes in brain function: a focused review,” Frontiers in Neuroscience, vol. 8, article 315, 2014. View at Publisher · View at Google Scholar
  6. F. G. de Felice and S. T. Ferreira, “Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease,” Diabetes, vol. 63, no. 7, pp. 2262–2272, 2014. View at Publisher · View at Google Scholar
  7. R. M. Peek Jr. and J. E. Crabtree, “Helicobacter infection and gastric neoplasia,” The Journal of Pathology, vol. 208, no. 2, pp. 233–248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Garcea, A. R. Dennison, W. P. Steward, and D. P. Berry, “Role of inflammation in pancreatic carcinogenesis and the implications for future therapy,” Pancreatology, vol. 5, no. 6, pp. 514–529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Murphy, L. A. Anderson, B. T. Johnston et al., “Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study,” World Journal of Gastroenterology, vol. 11, no. 46, pp. 7290–7295, 2005. View at Google Scholar · View at Scopus
  10. P. A. Vagefi and W. E. Longo, “Colorectal cancer in patients with inflammatory bowel disease,” Clinical Colorectal Cancer, vol. 4, no. 5, pp. 313–319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. W. G. Nelson, A. M. de Marzo, T. L. DeWeese et al., “The role of inflammation in the pathogenesis of prostate cancer,” The Journal of Urology, vol. 172, no. 5, pp. S6–S12, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Mantovani, “Cancer: inflammation by remote control,” Nature, vol. 435, no. 7043, pp. 752–753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. B. Vendramini-Costa and J. E. Carvalho, “Molecular link mechanisms between inflammation and cancer,” Current Pharmaceutical Design, vol. 18, no. 26, pp. 3831–3852, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Dong, E. Jimi, C. Zeiss, M. S. Hayden, and S. Ghosh, “Constitutively active NF-kappaB triggers systemic TNFalpha-dependent inflammation and localized TNFalpha-independent inflammatory disease,” Genes and Development, vol. 24, no. 16, pp. 1709–1717, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. C. Bharti, S. Shishodia, J. M. Reuben et al., “Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis,” Blood, vol. 103, no. 8, pp. 3175–3184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Nakshatri, P. Bhat-Nakshatri, D. A. Martin, R. J. Goulet Jr., and G. W. Sledge Jr., “Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 3629–3639, 1997. View at Google Scholar · View at Scopus
  18. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Shacter and S. A. Weitzman, “Chronic inflammation and cancer,” Oncology, vol. 16, no. 2, pp. 217–230, 2002. View at Google Scholar · View at Scopus
  20. J. G. Fox and T. C. Wang, “Inflammation, atrophy, and gastric cancer,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 60–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Dobrovolskaia and S. V. Kozlov, “Inflammation and cancer: When NF-κB amalgamates the perilous partnership,” Current Cancer Drug Targets, vol. 5, no. 5, pp. 325–344, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S. P. Hussain, L. J. Hofseth, and C. C. Harris, “Radical causes of cancer,” Nature Reviews Cancer, vol. 3, no. 4, pp. 276–285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Ben-Baruch, “Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 38–52, 2006. View at Publisher · View at Google Scholar
  24. M. J. Smyth, E. Cretney, M. H. Kershaw, and Y. Hayakawa, “Cytokines in cancer immunity and immunotherapy,” Immunological Reviews, vol. 202, no. 1, pp. 275–293, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Holliday, “Epigenetics: a historical overview,” Epigenetics, vol. 1, no. 2, pp. 76–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Meissner, “Epigenetic modifications in pluripotent and differentiated cells,” Nature Biotechnology, vol. 28, no. 10, pp. 1079–1088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. D. Smith and A. Meissner, “DNA methylation: roles in mammalian development,” Nature Reviews Genetics, vol. 14, no. 3, pp. 204–220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. A. J. Bannister and T. Kouzarides, “Regulation of chromatin by histone modifications,” Cell Research, vol. 21, no. 3, pp. 381–395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. M. Kohli and Y. Zhang, “TET enzymes, TDG and the dynamics of DNA demethylation,” Nature, vol. 502, no. 7472, pp. 472–479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. S. B. Rothbart and B. D. Strahl, “Interpreting the language of histone and DNA modifications,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1839, no. 8, pp. 627–643, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Morillon, N. Karabetsou, A. Nair, and J. Mellor, “Dynamic lysine methylation on histone H3 defines the regulatory phase of gene transcription,” Molecular Cell, vol. 18, no. 6, pp. 723–734, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Kouzarides, “Chromatin modifications and their function,” Cell, vol. 128, no. 4, pp. 693–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Eberharter and P. B. Becker, “Histone acetylation: a switch between repressive and permissive chromatin,” EMBO Reports, vol. 3, no. 3, pp. 224–229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Rea, F. Eisenhaber, D. O'Carroll et al., “Regulation of chromatin structure by site-specific histone H3 methyltransferases,” Nature, vol. 406, no. 6796, pp. 593–599, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Kouzarides, “Histone methylation in transcriptional control,” Current Opinion in Genetics and Development, vol. 12, no. 2, pp. 198–209, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. M. R. Mann and M. S. Bartolomei, “Epigenetic reprogramming in the mammalian embryo: struggle of the clones,” Genome Biology, vol. 3, no. 2, pp. 1003.1–1003.4, 2002. View at Google Scholar
  37. A. P. Bird, “CpG-rich islands and the function of DNA methylation,” Nature, vol. 321, no. 6067, pp. 209–213, 1986. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Lister, M. Pelizzola, R. H. Dowen et al., “Human DNA methylomes at base resolution show widespread epigenomic differences,” Nature, vol. 462, no. 7271, pp. 315–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Saxonov, P. Berg, and D. L. Brutlag, “A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1412–1417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Mohandas, R. S. Sparkes, and L. J. Shapiro, “Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation,” Science, vol. 211, no. 4480, pp. 393–396, 1981. View at Publisher · View at Google Scholar · View at Scopus
  41. S. J. Clark and J. Melki, “DNA methylation and gene silencing in cancer: which is the guilty party?” Oncogene, vol. 21, no. 35, pp. 5380–5387, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Kajdaniuk, B. Marek, H. Borgiel-Marek, and B. Kos-Kudła, “Transforming growth factor β1 (TGFβ1) in physiology and pathology,” Endokrynologia Polska, vol. 64, no. 5, pp. 384–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. H. You, W. Ding, and C. B. Rountree, “Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-β,” Hepatology, vol. 51, no. 5, pp. 1635–1644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Ding, M. Mouzaki, H. You et al., “CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis,” Hepatology, vol. 49, no. 4, pp. 1277–1286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Wang, H. Zhang, Q. Yao, Y. Wang, S. Dai, and X. Yang, “TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer,” Journal of Experimental and Clinical Cancer Research, vol. 31, no. 1, article 6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. N. Shah, G. Shao, T. K. Hei, and Y. Zhao, “Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR,” BMC Cancer, vol. 8, article 284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. Y.-Q. Wang, Y.-M. Li, X. Li et al., “Hypermethylation of TGF-β1 gene promoter in gastric cancer,” World Journal of Gastroenterology, vol. 19, no. 33, pp. 5557–5564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Shipitsin, L. L. Campbell, P. Argani et al., “Molecular definition of breast tumor heterogeneity,” Cancer Cell, vol. 11, no. 3, pp. 259–273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. H. K. Shin, Y.-J. Bang, Y.-H. Im et al., “Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer,” Oncogene, vol. 18, no. 51, pp. 7280–7286, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. S.-J. Kim, Y.-H. Im, S. D. Markowitz, and Y.-J. Bang, “Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis,” Cytokine and Growth Factor Reviews, vol. 11, no. 1-2, pp. 159–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Irigoyen, M. J. Pajares, J. Agorreta et al., “TGFBI expression is associated with a better response to chemotherapy in NSCLC,” Molecular Cancer, vol. 9, article 130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. N. I. Herath, B. A. Leggett, and G. A. MacDonald, “Review of genetic and epigenetic alterations in hepatocarcinogenesis,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, part 1, pp. 15–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Zhou, X. Zhang, and A. Klibanski, “Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma,” Molecular and Cellular Endocrinology, vol. 386, no. 1-2, pp. 16–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Amodio, D. Bellizzi, M. Leotta et al., “miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells,” Cell Cycle, vol. 12, no. 23, pp. 3650–3662, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Cheng, C. Huang, T.-T. Ma et al., “SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages,” Toxicology Letters, vol. 225, no. 3, pp. 488–497, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. P.-L. Kuo, K.-H. Shen, S.-H. Hung, and Y.-L. Hsu, “CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation,” Carcinogenesis, vol. 33, no. 12, Article ID bgs299, pp. 2477–2487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. J. S. You and P. A. Jones, “Cancer genetics and epigenetics: two sides of the same coin?” Cancer Cell, vol. 22, no. 1, pp. 9–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. Rosenzweig, J. D. Glenn, P. A. Calabresi, and K. A. Whartenby, “KLF4 modulates expression of IL-6 in dendritic cells via both promoter activation and epigenetic modification,” Journal of Biological Chemistry, vol. 288, no. 33, pp. 23868–23874, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. X. Tekpli, N. E. Landvik, K. H. Anmarkud, V. Skaug, A. Haugen, and S. Zienolddiny, “DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer,” Cancer Immunology, Immunotherapy, vol. 62, no. 2, pp. 337–345, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Shen, Z. He, H. Li et al., “Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes,” PLoS ONE, vol. 7, no. 9, Article ID e44822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Mocellin, E. Wang, and F. M. Marincola, “Cytokines and immune response in the tumor microenvironment,” Journal of Immunotherapy, vol. 24, no. 5, pp. 392–407, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. R. K. Singh, A. Sudhakar, and B. L. Lokeshwar, “Role of chemokines and chemokine receptors in prostate cancer development and progression,” Journal of Cancer Science & Therapy, vol. 2, no. 4, pp. 89–94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Starnes, K. K. Rasila, M. J. Robertson et al., “The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy,” Experimental Hematology, vol. 34, no. 8, pp. 1101–1105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. T. D. Shellenberger, M. Wang, M. Gujrati et al., “BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells,” Cancer Research, vol. 64, no. 22, pp. 8262–8270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. G. V. Shurin, R. Ferris, I. L. Tourkova et al., “Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by Dendritic Cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo,” The Journal of Immunology, vol. 174, no. 9, pp. 5490–5498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Y. Song, M. R. Shurin, I. L. Tourkova, D. W. Gutkin, and G. V. Shurin, “Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells,” Cancer Research, vol. 70, no. 11, pp. 4394–4401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Hu, F. Lin, G. Zhu et al., “Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer,” International Journal of Oncology, vol. 43, no. 5, pp. 1487–1494, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Cao, Y. Yang, Y. Pan et al., “Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion,” Discovery Medicine, vol. 16, no. 88, pp. 137–147, 2013. View at Google Scholar · View at Scopus
  69. N. Sato, H. Matsubayashi, N. Fukushima, and M. Goggins, “The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer,” Cancer Biology & Therapy, vol. 4, no. 1, pp. 70–76, 2005. View at Google Scholar
  70. T. Mori, J. Kim, T. Yamano et al., “Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells,” Cancer Research, vol. 65, no. 5, pp. 1800–1807, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. B. E. Lippitz, “Cytokine patterns in patients with cancer: a systematic review,” The Lancet Oncology, vol. 14, no. 6, pp. e218–e228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Müller, B. Homey, H. Soto et al., “Involvement of chemokine receptors in breast cancer metastasis,” Nature, vol. 410, no. 6824, pp. 50–56, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. E. A. S. Ramos, A. A. Camargo, K. Braun et al., “Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer,” BMC Cancer, vol. 10, no. 1, article 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. E. A. S. Ramos, M. Grochoski, K. Braun-Prado et al., “Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer,” PLoS ONE, vol. 6, no. 12, Article ID e29461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. A.-M. Baird, S. G. Gray, and K. J. O'Byrne, “Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer,” PLoS ONE, vol. 6, no. 1, Article ID e14593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. A.-M. Baird, S. G. Gray, and K. J. O'Byrne, “IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF,” European Journal of Cancer, vol. 47, no. 12, pp. 1908–1918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. M.-C. Cathcart, S. G. Gray, A.-M. Baird et al., “Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer,” Cancer, vol. 117, no. 22, pp. 5121–5132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. L. Langowski, X. Zhang, L. Wu et al., “IL-23 promotes tumour incidence and growth,” Nature, vol. 442, no. 7101, pp. 461–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. A.-M. Baird, J. Leonard, K. M. Naicker, L. Kilmartin, K. J. O'Byrne, and S. G. Gray, “IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer,” Lung Cancer, vol. 79, no. 1, pp. 83–90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. A.-M. Baird, É. Dockry, A. Daly et al., “IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer,” Frontiers in Oncology, vol. 3, article 162, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. I. Airoldi, E. Di Carlo, C. Cocco et al., “IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions,” PLoS ONE, vol. 4, no. 7, Article ID e6119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Airoldi, E. Di Carlo, B. Banelli et al., “The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignacies,” The Journal of Clinical Investigation, vol. 113, no. 11, pp. 1651–1659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. M. J. Brunda, L. Luistro, R. R. Warrier et al., “Antitumor and antimetastatic activity of interleukin 12 against murine tumors,” The Journal of Experimental Medicine, vol. 178, no. 4, pp. 1223–1230, 1993. View at Publisher · View at Google Scholar · View at Scopus
  84. M. P. Colombo and G. Trinchieri, “Interleukin-12 in anti-tumor immunity and immunotherapy,” Cytokine & Growth Factor Reviews, vol. 13, no. 2, pp. 155–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Dias, R. Boyd, and F. Balkwill, “IL-12 regulates VEGF and MMPs in a murine breast cancer model,” International Journal of Cancer, vol. 78, no. 3, pp. 361–365, 1998. View at Publisher · View at Google Scholar
  86. C. Sgadari, A. L. Angiolillo, and G. Tosato, “Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10,” Blood, vol. 87, no. 9, pp. 3877–3882, 1996. View at Google Scholar · View at Scopus
  87. E. E. Voest, B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman, “Inhibition of angiogenesis in vivo by interleukin 12,” Journal of the National Cancer Institute, vol. 87, no. 8, pp. 581–586, 1995. View at Publisher · View at Google Scholar · View at Scopus
  88. D. G. Duda, M. Sunamura, L. Lozonschi et al., “Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12,” Cancer Research, vol. 60, no. 4, pp. 1111–1116, 2000. View at Google Scholar · View at Scopus
  89. D. H. Presky, H. Yang, L. J. Minetti et al., “A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, pp. 14002–14007, 1996. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Airoldi, C. Cocco, E. di Carlo et al., “Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells,” Cancer Research, vol. 66, no. 8, pp. 3978–3980, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Suzuki, T. Iizasa, T. Nakajima et al., “Aberrant methylation of IL-12Rβ2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis,” Annals of Surgical Oncology, vol. 14, no. 9, pp. 2636–2642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Suzuki, H. Wada, M. Yoshino et al., “Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling,” Annals of Surgical Oncology, vol. 17, no. 3, pp. 878–888, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. C. H. T. Miller, S. G. Maher, and H. A. Young, “Clinical use of interferon-γ,” Annals of the New York Academy of Sciences, vol. 1182, pp. 69–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. M. R. Zaidi and G. Merlino, “The two faces of interferon-γ in cancer,” Clinical Cancer Research, vol. 17, no. 19, pp. 6118–6124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Ma, C. Jiang, X. Hu et al., “Methylation patterns of the IFN-gamma gene in cervical cancer tissues,” Scientific Reports, vol. 4, article 6331, 2014. View at Publisher · View at Google Scholar
  96. F. Wang, J. Xu, Q. Zhu et al., “Downregulation of IFNG in CD4+ T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression,” PLoS ONE, vol. 8, no. 11, Article ID e79064, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. H. Z. Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” Nature Reviews Cancer, vol. 2, no. 5, pp. 342–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. B. Rincon-Orozco, G. Halec, S. Rosenberger et al., “Epigenetic silencing of interferon-κ in human papillomavirus type 16-positive cells,” Cancer Research, vol. 69, no. 22, pp. 8718–8725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. C. B. Yoo, J. C. Cheng, and P. A. Jones, “Zebularine: a new drug for epigenetic therapy,” Biochemical Society Transactions, vol. 32, no. 6, pp. 910–912, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. E. Kaminskas, A. Farrell, S. Abraham et al., “Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes,” Clinical Cancer Research, vol. 11, no. 10, pp. 3604–3608, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Zhang and Q. Zhong, “Histone deacetylase inhibitors and cell death,” Cellular and Molecular Life Sciences, vol. 71, no. 20, pp. 3885–3901, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. E. E. Cameron, K. E. Bachman, S. Myöhänen, J. G. Herman, and S. B. Baylin, “Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer,” Nature Genetics, vol. 21, no. 1, pp. 103–107, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. M. A. Rudek, M. Zhao, P. He et al., “Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3906–3911, 2005. View at Publisher · View at Google Scholar · View at Scopus